XML 51 R25.htm IDEA: XBRL DOCUMENT v3.20.1
Collaboration and License Agreements - Amgen, Inc - Additional Information (Detail)
1 Months Ended 3 Months Ended 6 Months Ended
Sep. 28, 2016
USD ($)
Agreement
Dec. 31, 2019
USD ($)
Mar. 31, 2020
USD ($)
Mar. 31, 2019
USD ($)
Mar. 31, 2020
USD ($)
Mar. 31, 2019
USD ($)
Sep. 30, 2019
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Proceeds from the issuance of common stock   $ 250,500,000     $ 250,478,974 $ 60,521,729  
Revenues     $ 23,528,853 $ 48,148,275 52,983,433 $ 82,806,171  
Contract liabilities     $ 33,174,765   $ 33,174,765   $ 77,769,629
Type of Revenue [Extensible List]     arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember  
Collaboration and License agreements | Amgen              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Agreement date Sep. 28, 2016            
Number of agreements | Agreement 2            
Cash received as due under collaboration agreement $ 35,000,000            
AMG-890 (ARO-LPA) Agreement | Amgen              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Milestone payment 10,000,000            
AMG-890 (ARO-LPA) Agreement | Amgen | Maximum              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Development regulatory and sales milestones payments     $ 420,000,000   $ 420,000,000    
License Collaboration and Stock Purchase Agreement | Amgen              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Proceeds from the issuance of common stock $ 21,500,000            
AMG 890 (ARO-LPA) and ARO-AMG1 Agreement | Amgen              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Revenues     0 $ 300,000 0 $ 300,000  
Contract liabilities     0   0    
Contract assets     $ 0   $ 0    
Type of Revenue [Extensible List]     us-gaap:LicenseAndServiceMember us-gaap:LicenseAndServiceMember us-gaap:LicenseAndServiceMember us-gaap:LicenseAndServiceMember